Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

The average of price targets set by Wall Street analysts indicates a potential upside of 41.5% in Oruka Therapeutics, Inc. (ORKA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

ORKA-001 EVERLAST-A 16-week data now expected in 2Q 2026 following rapid enrollment, with longer-term follow-up data expected in 2H 2026

Oruka Therapeutics, Inc. has surged after ORKA-001 showed a half-life four times Skyrizi in Phase 1, targeting the $30B psoriasis market. ORKA-001 and ORKA-002 aim for best-in-class efficacy with dramatically less frequent dosing, potentially shifting the treatment paradigm for chronic skin diseases. Phase 2a EVERLAST-A results for ORKA-001 are expected in 2H26; meaningful revenue is not anticipated until 2031, highlighting ORKA stock's long-term, high-risk profile.

MENLO PARK, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced its participation and presentation at multiple upcoming conferences:

ORKA-002 interim Phase 1 data demonstrates a half-life of 75-80 days supporting potential for twice-per-year dosing in psoriasis and quarterly dosing in hidradenitis suppurativa Phase 2 studies for ORKA-002 expected to begin in 1H 2026 for psoriasis and 2H 2026 for hidradenitis suppurativa First patients dosed in EVERLAST-B Phase 2b trial of ORKA-001 in December 2025 with data expected in 2027 MENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO), today announced positive interim data from its Phase 1 trial of ORKA-002 and updates from the ongoing trials of ORKA-001.

MENLO PARK, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced that the Company will present at the 44th Annual J.P.

ORKA's main bet is by targeting psoriasis with ultra-durable biologics like ORKA-001 (IL-23) in Phase 2a and ORKA-002 (IL-17A/F) in Phase 1. ORKA-001 could offer significant clinical benefits with only 1 to 2 doses per year. Its Phase 1 suggests a ~100-day half-life. But interestingly, it's possible that higher exposure may drive higher clearance and potential off-treatment remission.